Background Despite unprecedented benefit from immune checkpoint inhibitors (ICIs) in
patients with mismatch repair deficient (dMMR)/microsatellite instability high (MSI-H) …

Malignant pleural effusion (MPE) is a serious complication of advanced tumor, with relatively
high morbidity and mortality rates, and can severely affect the quality of life and survival of …

Pleural and peritoneal metastasis accompanied by malignant pleural effusion (MPE) or
malignant ascites (MA) is frequent in patients with advanced solid tumors that originate from …

Abstract Background Malignant pleural effusions (MPEs) are a common complication of
advanced cancers, particularly those adjacent to the pleura, such as lung and breast cancer …

Introduction Malignant pleural effusion (MPE) is associated with poor treatment outcome in
patients with NSCLC receiving immune checkpoint inhibitors (ICIs). ICIs and chemotherapy …

Simple Summary Pleural effusion (PE) occurs as a consequence of various pathologies.
Malignant effusion due to lung cancer is one of the most frequent causes. A method for …

Isolation of tumor-specific T cells and their antigen receptors (TCRs) from malignant pleural
effusions (MPE) may facilitate the development of TCR-transduced adoptive cellular …

Introduction Malignant pleural effusion (MPE) is a frequent complication of advanced
malignancies. In this pilot study, we characterized the immune landscapes of MPEs …

Background Direct comparison of tumor microenvironment of matched lung cancer biopsies
and pleural effusions (PE) from the same patients is critical in understanding tumor biology …

Malignant pleural effusion (MPE), which is a complex microenvironment that contains
numerous immune and tumour signals, is common in lung cancer. Gene alterations, such as …